HemaFus RUNX1-RUNX1T1 Fusion Gene Quantitative Detection Kit(PCR-Fluorescent Probing) 

Background

The RUNX1-RUNX1T1 gene is one of the most common fusion genes in acute myeloid leukemia (AML). At the molecular level, the fusion is a result of t(8;21)(q22;q22) chromosomal translocation between the RUNX1 gene (previously known as AML1) on 21q22 and the RUNX1T1 gene (also known as ETO or MTG8) on 8q22. The expression product of this fusion gene is the RUNX1-RUNX1T1 fusion protein (Figure 1). This fusion gene is found in 6%–8% of primary AMLs, 20%–40% of M2, 90% of M2b, rarely in M4 and M1, and very rarely in MDS.

The presence of the RUNX1-RUNX1T1 fusion gene can serve as an important basis for molecular typing diagnosis and prognosis observation, and patients with positive RUNX1-RUNX1T1 have a better prognosis. RUNX1-RUNX1T1 positive leukemia cells have a certain degree of differentiation ability. It can differentiate into mature neutrophils and eosinophils, with better sensitivity to chemotherapy. They also have a good response to high-dose cytarabine treatment, which leads to a high remission rate and disease-free survival rate.

Figure 1

Detection Process

In this method, RNA is isolated and purified from leukocytes in peripheral blood or bone marrow samples, and cDNA is obtained by reverse transcription and the RUNX1-RUNX1T1 fusion gene will be detected by PCR-fluorescence probe method. The fusion gene status (Figure 2).

Kit Detection Results

Ordering Information